

Amendments to the Claims

1-40. (Cancelled)

41. (Currently amended) An aqueous liquid preparation consisting essentially of the following two components, wherein the first component is 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component is an alkyl aryl polyether alcohol type polymer or a polyethylene glycol fatty acid ester, wherein said liquid preparation is formulated for ophthalmic administration, and wherein when a quaternary ammonium compound is included in said liquid preparation, the quaternary ammonium compound is limited to benzalkonium chloride.

42. (Previously presented) The aqueous liquid preparation according to claim 41, wherein the second component is tyloxapol.

43. (Previously presented) The aqueous liquid preparation according to claim 41, wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt.

44. (Previously presented) The aqueous liquid preparation according to claim 41, wherein the second component is tyloxapol and the pharmacologically acceptable salt of 2-amino-3-(4-bromobenzoyl)phenylacetic acid is a sodium salt, wherein the concentration of the tyloxapol is from about 0.01 w/v % to about 0.5 w/v %; and

wherein the first component is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.01 to about 0.5 w/v %.

45. (Previously presented) The aqueous liquid preparation according to claim 44, wherein the concentration of the tyloxapol is from about 0.01 w/v % to about 0.3 w/v % and the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.05 to about 0.2 w/v %.

46. (Previously presented) The aqueous liquid preparation according to claim 45, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.1 w/v %.

47. (Previously presented) The aqueous liquid preparation according to claim 45, wherein the concentration of the tyloxapol is about 0.02 w/v %.

48. (Previously presented) The aqueous liquid preparation according to claim 41, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

49. (Previously presented) The aqueous liquid preparation according to claim 48, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said stabilizer is sodium sulfite; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

50. (Previously presented) The aqueous liquid preparation according to claim 49, wherein the pH is from about 7 to about 9.

51. (Previously presented) The aqueous liquid preparation according to claim 49, wherein the pH is from about 7.5 to about 8.5.

52. (Cancelled)

53. (Previously presented) The aqueous liquid preparation according to claim 45, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.2 w/v %.

54. (Previously presented) The aqueous liquid preparation according to claim 45, wherein the concentration of the tyloxapol is about 0.3 w/v %.

55. (Previously presented) The aqueous liquid preparation according to claim 54, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

56. (Previously presented) The aqueous liquid preparation according to claim 55, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said stabilizer is sodium sulfite; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

57. (Cancelled)

58. (Previously presented) The aqueous liquid preparation according to claim 53, wherein the concentration of the tyloxapol is about 0.02 w/v %.

59. (Previously presented) The aqueous liquid preparation according to claim 58, wherein the formulation further includes one or more additives selected from the group consisting of a preservative, buffer, thickener, stabilizer, chelating agent, and pH controlling agent.

60. (Previously presented) The aqueous liquid preparation according to claim 59, wherein said preservative is benzalkonium chloride; wherein said buffer is boric acid and/or sodium borate; wherein said thickener is polyvinylpyrrolidone; wherein said chelating agent is sodium edetate; and wherein said pH controlling agent is sodium hydroxide.

61. (Withdrawn-Currently amended) A method for stabilizing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate

thereof in an aqueous liquid preparation, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, to obtain an aqueous liquid preparation consisting essentially of the following two components, the first component being 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component being tyloxapol or polyethylene glycol monostearate, wherein said liquid preparation is formulated for ophthalmic administration, and wherein when a quaternary ammonium compound is included in said liquid preparation, the quaternary ammonium compound is limited to benzalkonium chloride.

62. (Withdrawn-Currently amended) A method for inhibiting decrease in preservative effect of a preservative in an aqueous liquid preparation of 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof and a preservative, to obtain an aqueous liquid preparation consisting essentially of the following two components, the first component being 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and the second component being tyloxapol or polyethylene glycol monostearate, together with a preservative, wherein said liquid preparation is formulated for ophthalmic administration, and wherein when a quaternary ammonium compound is included in said liquid preparation, the quaternary ammonium compound is limited to benzalkonium chloride.

63. (Cancelled)

64. (Currently amended) An aqueous liquid preparation consisting essentially of:
(a) 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof,
(b) tyloxapol,

- (c) boric acid,
- (d) sodium tetraborate,
- (e) EDTA sodium salt,
- (f) benzalkonium chloride,
- (g) polyvinylpyrrolidone, and
- (h) sodium sulfite, ~~and~~

wherein said liquid preparation is formulated for ophthalmic administration, and
wherein benzalkonium chloride is the only quaternary ammonium compound which is included
in said liquid preparation.

65. (Previously presented) The aqueous liquid preparation of claim 64, wherein (a) is a 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt.

66. (Previously presented) The aqueous liquid preparation of claim 65, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is from about 0.01 to about 0.5 w/v % and the concentration of the tyloxapol is about 0.02 w/v %.

67. (Previously presented) The aqueous liquid preparation of claim 66, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.01 w/v %.

68. (Previously presented) The aqueous liquid preparation of claim 66, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid sodium salt is about 0.1 w/v %.